Summary Background Tenofovir alafenamide (TAF) has exhibited a favourable safety profile on estimated glomerular filtration (eGFR) and bone mineral density (BMD), but has not been extensively studied in patients with renal impairment and/or BMD disorders. Aims To assess predictors of eGFR changes and other safety and efficacy outcomes during 24‐month TAF therapy in patients with chronic hepatitis B with renal and/or BMD disorders/risks. Methods Adult patients who started TAF at 13 clinics throughout Greece were prospectively included. Main exclusion criteria were hepatitis D, active malignancy and bisphosphonates recent use. MDRD formula was used for eGFR estimation. Results TAF was initiated in 176 patients (91% switched from another agent). At 12 and 24 months, HBV DNA was undetectable in 97% and 100%, and ALT was normal in 96% and 95% of patients. Median ALT decreased from baseline to month 12/24 (p < 0.001). Mean eGFR decreased from previous treatment initiation to baseline (p < 0.001), increased at 12 months and remained stable at 24 months (p ≤ 0.001). An increase in eGFR of >3 ml/min at 12 month was observed in 50% of patients and was associated mainly with baseline eGFR 30–60 ml/min. In patients with baseline phosphate <2.5 mg/dl, mean serum phosphate increased at month‐12/24 (p < 0.001). Median BMD did not change significantly from baseline to 12 months but improved at 24 months (p = 0.001). Conclusions In mostly switched patients with renal and/or BMD disorders/risks, eGFR improved after 12‐24 months of TAF treatment, especially in patients with baseline eGFR 30–60 ml/min. TAF may also improve low serum phosphate, BMD and ALT, whereas it maintains or induces virological suppression.

No abstract

Introduction: The dissemination and adoption of healthy eating habits are crucial in promoting Public Health. Metabolic syndrome increases the risk of developing diabetes and cardiovascular disease, a leading cause of death. Viral hepatitis causes a high morbidity burden and a high incidence of hepatocellular carcinoma.Objective: This case-control aims to investigate the impact of eating habits, especially functional food, on biomarkers of Metabolic Syndrome, Hepatitis B/C. The bibliographic lack of research on this matter was the impetus for this study.Methods: 90 (aged> 18 years) patients participated in the study, equally distributed in the three diseases and 90 healthy controls. The cardiovascular-hepatic biomarkers evaluated were: HbΑ1c, CHOL, TG, HDL, SGOT, SGPT, ΝΤ-proBNP, U, and CR.Results: The main groups of conventional and selected functional foods were recorded through their frequency of consumption and their effect on biomarkers (Statistically significant level, p-value <0.05). BNP was statistically significantly correlated (<300 pg./ml) with the consumption of wine, legumes, and honey, Urea with the consumption of fruits, Cr with the consumption of nuts and olive oil, and Cholesterol with the consumption of honey and herbs. Increased consumption of nuts was statistically significantly correlated with the improvement of BNP and U-values, vegetables with the improvement of SGPT, coffee fruits, and herbs with the improvement of SGOT values.Conclusion: Our results agree with the international references, where the beneficial effects of functional foods are mainly captured descriptively and not in absolute values of biomarkers, as we have tried to highlight in our case-report study. Although in a small sample, the results highlight the beneficial effect of functional foods on cardiovascular-hepatic biomarkers. More prospective studies are needed for clearer results.Keywords: Functional Food; Metabolic Syndrome; Hepatitis B; Hepatitis C; Biomarkers

No abstract

No abstract